News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer
A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time.
The last seven days have seen important breakthroughs in the treatment of dermatitis in younger children, metastatic colorectal cancer and desmoid tumours, while drugs for Alzheimer’s disease and psoriasis have overcome regulatory hurdles in the US.
This week’s top stories:
A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial.
A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer.
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s allosteric tyrosine kinase 2 inhibitor Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.
Ayala Pharmaceuticals has revealed positive interim results from its ongoing RINGSIDE Pivotal Phase II and III clinical trial into gamma-secretase inhibitor AL102 in desmoid tumours.
The United States Patent Office (USPTO) has issued a patent covering drug candidate ACD856, which is currently being developed to treat Alzheimer’s disease and other disorders with cognitive impairment.